Published in final edited form as:

Cancer. 2020 January 01; 126(9): 2034–2035. doi:10.1002/cncr.32727.

Reply to On the Proportion of Male Breast Cancer Among All Breast Cancers

Siddhartha Yadav, MD,

Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota

Dhauna Karam, MD

Department of Community Internal Medicine, Mayo Clinic Health System at Austin and Albert Lea, Albert Lea, Minnesota

Irbaz Bin Riaz, MD, Hao Xie, MD, PhD, Urshila Durani, MD

Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota

Narjust Duma, MD,

Division of Oncology, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Karthik V. Giridhar, MD

Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota

Tina J. Hieken, MD, Judy C. Boughey, MD

Department of Surgery, Mayo Clinic, Rochester, Minnesota

Robert W. Mutter, MD,

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota

John R. Hawse, PhD

Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota

Rafael E. Jimenez, MD, Fergus J. Couch, PhD

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota

Roberto A. Leon Ferre, MD, Kathryn J. Ruddy, MD, MPH

Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota

We thank Xu et al for their interest in our article.¹ As they mention in their letter, the proportion of male breast cancer (MBC) among all breast cancer cases in the United States is approximately 1%,² not exactly 1.00%. We agree with Xu et al that other studies have identified geographical variations in MBC prevalence across different continents. However, given that our study reports on US data only and does not evaluate the incidence or prevalence of MBC, we thought that it was most appropriate to describe US statistics in our report. One contributing factor to the higher relative incidence of MBC outside the United

CONFLICT OF INTEREST DISCLOSURES

Karthik V. Giridhar reports travel costs paid to his institution by Menarini Silicon Biosystems to attend an investigators' meeting for work performed outside the current study. Tina J. Hieken has received grants from Genentech for work performed outside the current study. Roberto A. Leon-Ferre has received travel support from Immunomedics for work performed outside the current study. Kathryn J. Ruddy inherited and then sold stock in Pfizer and Merck in February 2018. The other authors made no disclosures.

States may be that lower rates of screening mammography in women in some regions limit female breast cancer diagnoses, and this elevates the relative proportion of diagnosed cases that occur in men. In addition, several of the studies mentioned by Xu et al were not population-based, and this means that an ascertainment bias may have influenced those results. Additional research is needed to truly understand the racial and geographical variations in MBC incidence and prevalence across different populations in the world.

FUNDING SUPPORT

No specific funding was disclosed.

REFERENCES

1. Yadav S, Karam D, Bin Riaz I, et al. Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century. *Cancer*. 2020;126:26–36. [PubMed: 31588557]
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin*. 2018;68:7–30. [PubMed: 29313949]